LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Andrew J. Armstrong, Taro Iguchi, Arun Azad, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, B. Yа. Alekseev, Neal D. Shore, Daniel P. Petrylak, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl